Abstract
Ischemia-modified albumin (IMA) is a novel marker of tissue ischemia. Nowadays, IMA is accepted as a marker of oxidative stress. In this study, we aimed at establishing an association between IMA and hyperglycemia, blood pressure, lipid parameters, microvascular complications, hsCRP, and microalbuminuria in type 2 diabetes patients without overt macrovascular disease and acute ischemia. Fifty type 2 diabetes mellitus patients without a history of macrovascular disease or end-stage renal disease were enrolled into the study. Age-matched 30 healthy individuals were also included in the study as a control group. Plasma IMA (0.329 ± 0.046 and 0.265 ± 0.045 AbsU; P < 0.0001) and hsCRP levels (0.51 ± 0.36 and 0.32 ± 0.17 mg/dl; P < 0.0001) were significantly higher in the diabetic group compared to healthy controls. IMA level was significantly correlated with hsCRP (r = 0.76; P < 0.0001), HbA1c (r = 0.72; P < 0.0001), microalbuminuria (r = 0.40; P = 0.004), systolic blood pressure (r = 0.28; P = 0.049), diastolic blood pressure (r = 0.44; P = 0.005), and HOMA-IR (r = 0.42; P = 0.005) levels in the entire diabetic subjects. In the diabetic patients group, presence of microalbuminuria was associated with a higher plasma IMA level (0.355 ± 0.035 and 0.265 ± 0.0045 AbsU; P < 0.0001, patients with microalbuminuria and control subjects, respectively). In the type 2 diabetes patients with nephropathy, IMA level (0.355 ± 0.035 and 0.311 ± 0.046 AbsU; P = 0.002) was determined higher compared to the diabetes patients without nephropathy. Diabetic patients without an overt cardiovascular disease still have a higher serum IMA level compared to healthy controls. The correlation of high plasma IMA levels with high hsCRP and microalbuminuria levels in diabetic subjects indicates the presence of a chronic ischemic process. Therefore, elevated IMA levels may indicate an underlying subclinical vascular disease in type 2 diabetes mellitus patients.
Similar content being viewed by others
References
P. Libby, Circulation 91, 2844–2850 (1995)
P. Libby, P.M. Ridker, Circulation 100, 1148–1150 (1999)
R. Ross, N. Engl. J. Med. 340, 115–126 (1999)
F.B. Hu, M.J. Stampfer, S.M. Haffner, C.G. Solomon, W.C. Willett, J.E. Manson, Diabetes Care 25, 1129–1134 (2002)
J.J. de, J.M. Dekker, A. Kooy, P.J. Kostense, G. Nijpels, R.J. Heine, L.M. Bouter, C.D. Stehouwer, Arterioscler. Thromb. Vasc. Biol. 26, 1086–1093 (2006)
C.E. Mogensen, P.L. Poulsen, Curr. Opin. Nephrol. Hypertens. 3, 248–256 (1994)
F. Perticone, R. Ceravolo, A. Pujia, G. Ventura, S. Iacopino, A. Scozzafava, A. Ferraro, M. Chello, P. Mastroroberto, P. Verdecchia, G. Schillaci, Circulation 104, 191–196 (2001)
N. Rifai, P.M. Ridker, Clin. Chem. 47, 403–411 (2001)
P.J. Sadler, A. Tucker, J.H. Viles, Eur J. Biochem. 220, 193–200 (1994)
P.O. Collinson, D.C. Gaze, J. Clin. Pathol. 61, 1025–1028 (2008)
J. Dusek, J. St’asek, M. Tichy, J. Bis, J. Gregor, J. Vojacek, V. Masin, P. Polansky, M. Brtko, D. Cernohorsky, Clin. Chim. Acta. 367, 77–80 (2006)
H. Abboud, J. Labreuche, E. Meseguer, P.C. Lavallee, O. Simon, J.M. Olivot, M. Mazighi, M. Dehoux, J. Benessiano, P.G. Steg, P. Amarenco, Cerebrovasc. Dis. 23, 216–220 (2007)
R. Sharma, D.C. Gaze, D. Pellerin, R.L. Mehta, H. Gregson, C.P. Streather, P.O. Collinson, S.J. Brecker, Am. J. Kidney Dis. 47, 493–502 (2006)
R. Sharma, D.C. Gaze, D. Pellerin, R.L. Mehta, H. Gregson, C.P. Streather, P.O. Collinson, S.J. Brecker, Clin. Sci. (Lond.) 113, 25–32 (2007)
S. Turedi, A. Gunduz, A. Mentese, S.C. Karahan, S.E. Yilmaz, O. Eroglu, I. Nuhoglu, I. Turan, M. Topbas, Am. J. Emerg. Med. 25, 770–773 (2007)
D. Borderie, Y. Allanore, C. Meune, J.Y. Devaux, O.G. Ekindjian, A. Kahan, Clin. Chem. 50, 2190–2193 (2004)
M. Senes, N. Kazan, O. Coskun, O. Zengi, L. Inan, D. Yucel, Ann. Clin. Biochem. 44, 43–47 (2007)
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Diabetologia 28, 412–419 (1985)
D. Bar-Or, E. Lau, J.V. Winkler, J. Emerg. Med. 19, 311–315 (2000)
S. Turedi, A. Gunduz, A. Mentese, B. Dasdibi, S.C. Karahan, A. Sahin, G. Tuten, M. Kopuz, A. Alver, J. Resusc. doi:10.1016/j.resuscitation.2009.06.007
M. Kalousova, A. Zak, J. Soukupova, S. Stipek, I.M. Malbohan, T. Zima, Cas. Lek. Cesk. 144, 385–389 (2005)
E.R. Stadtman, B.S. Berlett, Drug Metab. Rev. 30, 225–243 (1998)
S.C. Satchell, J.E. Tooke, Diabetologia 51, 714–725 (2008)
T. Munzel, C. Sinning, F. Post, A. Warnholtz, E. Schulz, Ann. Med. 40, 180–196 (2008)
G. Lippi, M. Montagnana, G.C. Guidi, Int. J. Cardiol. 108, 410–411 (2006)
A. Piwowar, M. Knapik-Kordecka, M. Warwas, Dis. Markers 24, 311–317 (2008)
P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. Macfadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn, N. Engl. J. Med. 359, 2195–2207 (2008)
A.S. Ametov, T.I. Demidova, S.A. Kosykh, Klin. Med. (Mosk) 83, 62–68 (2005)
J.A. Suwaidi, S. Hamasaki, S.T. Higano, R.A. Nishimura, D.R. Holmes Jr., A. Lerman, Circulation 101, 948–954 (2000)
Acknowledgments
Part of this study was presented in 41st Annual Meeting of EASD (Athens–2005) printed as an abstract in Diabetologia 48(S1): A409;2005.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ukinc, K., Eminagaoglu, S., Ersoz, H.O. et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocr 36, 425–432 (2009). https://doi.org/10.1007/s12020-009-9236-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-009-9236-5